Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Mol Cancer Ther. 2016 Nov 9;16(1):124–133. doi: 10.1158/1535-7163.MCT-16-0503

Figure 2.

Figure 2

Biodistribution data obtained from an in vivo pretargeting experiment in which 177Lu-DOTA-PEG7-Tz (2 nmol) was injected 72 h after the administration of 5B1-TCO (1.3 nmol). The activity concentrations in selected tissues at time points ranging from 4 to 120 h after the injection of 177Lu-DOTA-PEG7-Tz were determined along with selected tumor-to-tissue activity concentration ratios (inset).